

Provided by:



Plasma Cell Dyscrasias Case Conference 2022-2023

Plasma Cell Dyscrasias Case Conference 2022-2023 - 7/8/2022

July 8, 2022

12:00 PM - 1:00 PM

Perelman Center for Advanced Medicine, SPE, Conference Room 12-122

Target Audience

This program has been designed for Internal Medicine - Hematology, Internal Medicine - Medical Oncology, Pathology - Clinical

Series Educational Objectives

After participating in this regularly scheduled series, participants should be able to:

- 1 Diagnose various plasma cell dyscrasias and distinguish between pre-cancerous (MGUS/smoldering) and malignant (multiple myeloma) conditions.
- 2 Discuss standard-of-care treatment for patients with plasma cell dyscrasias and harmonize practice patterns.
- 3 Incorporate recently published/presented research and practice guidelines into local practice and pathways.

Accreditation

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physicians: Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: This activity is for **1.00** contact hours.

Pharmacists: This activity is approved for **1.00** contact hours

UAN Number: JA0000324-0000-22-046-L04-P

PAs: Penn Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria.

This activity is designated for **1.00** AAPA Category 1 CME credit(s). PAs should only claim credit commensurate with the extent of their participation.

Approved for (PSRM) patient safety/risk management designation

Acknowledgement of Commercial Support*

None

For more information, please contact
Cherylann Lane, Julie Mcdaniel
(215) 662-3181, (267) 970-8367

cherylann.lane@uphs.upenn.edu, mcdjulie@upenn.edu

Check your transcript online at <https://upenn.cloud-cme.com>

Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships that they have with any commercial interest that provide products or services that may be relevant to the content of this continuing education activity. For this purpose, we consider relationships of the person involved to include financial relationships of a spouse or partner.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are based on valid content, and are independent of control from commercial interests and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain relationships that created a conflict of interest relevant to the topic of their presentation. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no relevant financial relationships with any commercial interests related to the content of this educational activity. Any peer reviewer with a potential conflict of interest will recuse themselves from the peer review process.

Name of individual	Individual's role in activity	Name of Ineligible Company(s) / Nature of Relationship(s)
Adam Waxman, M.D.	Co-Director, Faculty	Nothing to disclose - 01/20/2022
Alfred L L. Garfall, MD, MS	Course Director	Consulting Fee-Janssen Pharmaceuticals (J&J) Consulting Fee-Amgen (Relationship has ended) Grant or research support-Novartis (Advanced Health Media) Grant or research support-Janssen Pharmaceuticals (J&J) Grant or research support-tmunity Grant or research support-crispr therapeuics - 06/17/2022
Patricia Mangan, CRNP	Nurse Planner	Advisor-Janssen Pharmaceuticals (J&J) Honoraria-Bristol-Myers Squibb - 01/14/2022
Adam D. Cohen	Other Planning Committee Member	Membership on Advisory Committees or Review Panels, Board Membership, etc.- Janssen Pharmaceuticals (J&J) Membership on Advisory Committees or Review Panels, Board Membership, etc.-Takeda Pharmaceuticals (Relationship has ended) Membership on Advisory Committees or Review Panels, Board Membership, etc.-Bristol-Myers Squibb Membership on Advisory Committees or Review Panels, Board Membership, etc.- Oncopeptides (Relationship has

		ended) Membership on Advisory Committees or Review Panels, Board Membership, etc.-Astra Zeneca Pharmaceuticals (Relationship has ended) Membership on Advisory Committees or Review Panels, Board Membership, etc.-Genentech Membership on Advisory Committees or Review Panels, Board Membership, etc.-Seattle Genetics (Relationship has ended) Grant or research support-Glaxo Smith Kline Membership on Advisory Committees or Review Panels, Board Membership, etc.-Glaxo Smith Kline Membership on Advisory Committees or Review Panels, Board Membership, etc.- Arcellix Grant or research support-Novartis (Advanced Health Media) - 11/11/2021
Edward A A. Stadtmauer, MD	Other Planning Committee Member	Grant or research support-AbbVie, Inc. Consulting Fee-Glaxo Smith Kline (Relationship has ended) Consulting Fee-Sanofi Genzyme (Relationship has ended) Consulting Fee-Bristol-Myers Squibb (Relationship has ended) Consulting Fee-Amgen - 12/10/2021
Dan T. Vogl, MD, MSCE	Other Planning Committee Member	Consulting Fee-Takeda Pharmaceuticals (Relationship has ended) Consulting Fee-Glaxo Smith Kline (Relationship has ended) Consulting Fee-Karyopharm Grant or research support-Takeda Pharmaceuticals Grant or research support-Active Biotech Consulting Fee-Oncopeptides (Relationship has ended) Consulting Fee-CSL Behring (Relationship has ended) Consulting Fee-Sanofi Genzyme (Relationship has ended) - 04/20/2022
Colleen Timlin, RPH	Pharmacy Planner	Nothing to disclose - 01/11/2022
Jessica Heaven, PA-C	Physician Assistant Planner	Nothing to disclose - 01/20/2022

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected